OverviewSuggest Edit

Allergan is a healthcare company. It focuses on discovering, developing, and commercializing of innovative pharmaceuticals, biologics, and medical devices.
TypePublic
Founded1948
HQDublin, IE
Websiteallergan.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2019)17,400(+3%)
Job Openings23
Revenue (FY, 2019)$16.1 B(+2%)
Share Price (May 2020)$193
Cybersecurity ratingCMore

Key People/Management at Allergan

Richard A. Gonzalez

Richard A. Gonzalez

Chairman of the Board and Chief Executive Officer
Roxanne S. Austin

Roxanne S. Austin

Director
William H.l. Burnside

William H.l. Burnside

Director
Edward M. Liddy

Edward M. Liddy

Director
Edward J. Rapp

Edward J. Rapp

Director
Melody Meyer

Melody Meyer

Director
Show more

Allergan Office Locations

Allergan has offices in Dublin, Dublin 13, Dublin 17, Dublin 2 and in 70 other locations
Gordon, AU
Level 4/810 Pacific Hwy
Wien, AT
Twin Tower, Wienerbergstraße 11/12A
Manama, BH
806 Rd No 3315
Dhaka, BD
50 Purana Paltan Line
Machelen, BE
De Kleetlaan 4
Cochabamba, BO
Mayor Rocha 250
Show all (100)

Allergan Financials and Metrics

Allergan Revenue

Embed Graph
View revenue for all periods
Allergan's revenue was reported to be $16.09 b in FY, 2019 which is a 1.9% increase from the previous period.
USD

Revenue (Q1, 2020)

3.6b

Gross profit (Q1, 2020)

3.0b

Gross profit margin (Q1, 2020), %

82.7%

Net income (Q1, 2020)

249.8m

EBIT (Q1, 2020)

(1.3b)

Market capitalization (14-May-2020)

63.7b

Closing stock price (14-May-2020)

193.0

Cash (31-Mar-2020)

999.5m

EV

65.2b
Allergan's current market capitalization is $63.7 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

15.9b15.8b16.1b

Revenue growth, %

9%(1%)2%

Cost of goods sold

2.2b2.2b2.5b

Gross profit

13.8b13.6b13.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

3.7b4.1b3.9b3.6b4.1b4.1b3.6b

Cost of goods sold

522.8m481.8m596.8m497.8m652.3m639.0m623.1m

Gross profit

3.1b3.6b3.3b3.1b3.4b3.4b3.0b

Gross profit Margin, %

86%88%85%86%84%84%83%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.8b880.4m2.5b

Accounts Receivable

2.9b2.9b3.2b

Inventories

904.5m846.9m1.1b

Current Assets

11.4b6.5b11.1b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

994.8m1.7b1.2b788.5m1.7b1.2b999.5m

Accounts Receivable

2.6b2.8b2.8b2.7b3.1b3.0b2.8b

Prepaid Expenses

855.3m

Inventories

948.4m922.5m894.6m943.2m1.0b1.1b1.2b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(4.1b)(5.1b)(5.3b)

Depreciation and Amortization

7.4b6.7b6.1b

Inventories

(144.8m)(145.7m)(393.4m)

Accounts Payable

95.9m151.6m1.4b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(283.9m)(754.0m)(790.3m)(2.4b)(4.2b)(4.9b)

Depreciation and Amortization

1.8b3.5b5.1b1.4b2.9b4.5b1.5b

Inventories

(52.7m)(113.3m)(136.2m)(128.3m)(179.3m)(328.9m)(126.3m)

Accounts Payable

(231.6m)(40.4m)(46.1m)(199.8m)161.6m874.9m(1.2b)
USDFY, 2017

EV/EBIT

-14 x

EV/CFO

14.1 x

Revenue/Employee

895.5k

Debt/Equity

0.4 x

Debt/Assets

0.3 x

Financial Leverage

1.6 x

P/E Ratio

(12.3)
Show all financial metrics

Allergan Operating Metrics

FY, 2016Q1, 2017Q2, 2017Q3, 2017FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019

Countries

100 100 100 100 100 100 100 100 100 100 100 100 100

Key Promoted Products

36 25 17 18

Facilities

17 21 21 21

Facilities Leased

7 11 11 11
Show all operating metrics

Allergan Acquisitions / Subsidiaries

Company NameDateDeal Size
BontiSeptember 14, 2018$195 m
ElastagenFebruary 07, 2018$95 m
Repros TherapeuticsDecember 12, 2017
ZELTIQ Aesthetics (CoolSculpting)February 15, 2017$2.48 b
Lysosomal TherapeuticsJanuary 09, 2017
LifeCellDecember 20, 2016$2.90 b
Chase PharmaceuticalsNovember 22, 2016$125 m
Motus TherapeuticsOctober 27, 2016$200 m
Akarna TherapeuticsSeptember 20, 2016
Tobira TherapeuticsSeptember 20, 2016$1.70 b
Show more

Allergan Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Allergan Revenue Breakdown

Embed Graph

Allergan revenue breakdown by business segment: 21.1% from International, 36.3% from US General Medicine, 42.4% from US Specialized Therapeutics and 0.2% from Other

Allergan Online and Social Media Presence

Embed Graph

Allergan News and Updates

AGN Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Allergan plc and Lead Plaintiff Deadline – October 29, 2020

NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allergan plc ("Allergan" or the "Company") (NYSE: AGN) and certain of its officers, on behalf of shareholders who purchase…

Dermal Fillers Market is Expected to Rise at a CAGR of 7.8% and to Reach USD 6,303.2 Million; Allergan Launches a New Dermal Filler to Expand its Customer Reach: Fortune Business Insights

Key Companies Covered in the Dermal Fillers Market Research Report Are BioPlus Co., Ltd., Galderma laboratories, Bioxis pharmaceuticals, Suneva Medical, DR. Korman, Sinclair Pharma, ALLERGAN, Merz Pharma, and CANDELA CORPORATION and other key market players Key Companies Covered in the Dermal Filler…

Global Acne Drugs Markets 2020-2025 with Profiles of Allergan, Bausch Health, Galderma, GlaxoSmithKline, and Pfizer

Dublin, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The "Acne Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.

United States Acne and Rosacea Industry Insights 2020-2024 - Leading Players are Allergan, Bausch Health Companies, Leo Pharma, Sol Gel Technologies, Foamix Pharmaceuticals and Galderma

DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering. The US acne market is expected to reach US$4.49 billion in 2024, recording growth at a CAGR of 4.12% during the period...

Medical Botox 2020 Global Market Key Players - Allergan, Ipsen, Medytox, US World Meds, Merz Pharmaceuticals, LIBP-Analysis And Forecast To 2026

New Study Reports “Medical Botox – Covid-19 impact on Global Market Growth, Opportunities, Analysis of Top Key Players and Forecast to 2026” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Evolus Botox Rival Loses First Round Over AbbVie’s Allergan

Evolus Botox Rival Loses First Round Over AbbVie’s Allergan
Show more

Allergan Blogs

Allergan Provides Online Resource for Patients and Surgeons about BIOCELL® Textured Breast Implants and Tissue Expanders

Allergan plc (NYSE: AGN) today launched an online resource at www.BIOCELLinformation.com for patients, surgeons and healthcare professionals related to the voluntary global recall of BIOCELL®  textured breast implants and tissue expanders announced on July 24, 2019.

Allergan Reports Second Quarter 2019 Financial Results

- Q2 2019 GAAP Net Revenues of $4.09 Billion - - Q2 2019 GAAP Loss Per Share of $5.37; Non-GAAP Performance Net Income Per Share of $4.38 - - Q2 2019 GAAP Operating Loss of $1.26 Billion; Non-GAAP O...

Allergan to Report Second Quarter 2019 Financial Results

DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.S. financial mark...

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign

Actress encourages women to take active roles in their reproductive health, including researching birth control options DUBLIN, July 29, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced to...

Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders

-- Global Action Follows Notification of Updated Safety Information from the U.S. Food and Drug Administration (FDA) --  -- FDA Does Not Recommend Removal or Replacement of Textured Breast Implants i...

Allergan Declares Third Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share

- Dividend to be Paid on September 13, 2019 - - Record Date of August 13, 2019 - DUBLIN, July 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has de...
Show more

Allergan Frequently Asked Questions

  • When was Allergan founded?

    Allergan was founded in 1948.

  • Who are Allergan key executives?

    Allergan's key executives are Richard A. Gonzalez, Roxanne S. Austin and William H.l. Burnside.

  • How many employees does Allergan have?

    Allergan has 17,400 employees.

  • What is Allergan revenue?

    Latest Allergan annual revenue is $16.1 b.

  • What is Allergan revenue per employee?

    Latest Allergan revenue per employee is $924.6 k.

  • Who are Allergan competitors?

    Competitors of Allergan include Teva Pharmaceuticals, Hancock Jaffe and Microbion.

  • Where are Allergan offices?

    Allergan has offices in Dublin, Dublin 13, Dublin 17, Dublin 2 and in 70 other locations.

  • How many offices does Allergan have?

    Allergan has 100 offices.